Merck and Moderna to jointly develop personalised cancer vaccine
Drug Discovery World
NOVEMBER 8, 2022
Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . KEYNOTE-942 is an ongoing randomised, open-label Phase II trial that enrolled 157 patients with high-risk melanoma.
Let's personalize your content